Charles River Laboratories (CRL) Stock Price, Fundamentals & Analysis

What CRL does

Charles River Laboratories (CRL) provides drug discovery, non-clinical development, and safety testing services across the United States, Europe, Canada, the Asia Pacific, and internationally. The company operates through two main segments: Research Models and Services, which produces rodents and purpose-bred rats and mice for researchers and offers services such as genetically engineered models, insourcing solutions, and research animal diagnostics; and Discovery and Safety Assessment, which delivers in vitro and in vivo discovery services, safety assessment (including toxicology, pathology, and pharmacokinetics), and vivarium space services. CRL is part of the S&P 500 and operates in the Healthcare sector, specifically Diagnostics & Research.

Key numbers explained

• 277,33 USD is the current share price, the amount you would pay for one share right now.
• -2.73% is the price change today, showing the stock moved down by that percentage over the trading session.
• 13.24B USD is the market capitalisation, the total value of all outstanding shares.
• The forward P/E ratio of 21.8 compares the current price to expected future earnings; a higher number can mean the market expects strong growth.
• The dividend yield of 0% means the company does not currently pay a cash dividend to shareholders.
• -4.82 USD is the trailing 12-month earnings per share, reflecting a net loss over the past year.
• 1.41 is the beta, indicating the stock tends to be more volatile than the overall market.
• The 52-week range of 144,26 – 303,31 shows the lowest and highest prices over the past year.

Recent news

Recent headlines highlight competition in pharmacokinetics outsourcing, toxicology testing, and drug discovery services, with Charles River Laboratories benchmarked alongside peers such as Labcorp (LH), WuXi AppTec, Eurofins, and others. Articles also frame CRL among stocks navigating a fine line and discuss fragment-based strategies in drug discovery through 2030.

What to watch

Investors typically monitor CRL in relation to broader trends in drug discovery outsourcing, regulatory changes affecting safety testing, and competitive dynamics with peers like Labcorp (LH), DaVita (DVA), and Zoetis (ZTS). The company's financial trajectory will be shaped by revenue growth, margin performance, and its ability to convert operating strength into bottom-line profitability.